Human medicines European public assessment report (EPAR): Ocrevus, ocrelizumab, Multiple Sclerosis, Date of authorisation: 08/01/2018, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Ocrevus, ocrelizumab, Multiple Sclerosis, Date of authorisation: 08/01/2018, Revision: 18, Status: Authorised

Nitrosamines EMEA-H-A5(3)-1490 - Questions and answers for marketing authorisation holders / applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products

Nitrosamines EMEA-H-A5(3)-1490 - Questions and answers for marketing authorisation holders / applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness